Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2500675 | Farmacia Hospitalaria | 2006 | 9 Pages |
Abstract
BIA models can be useful for the inclusion or reassessment of drugs in formularies. In this case, the treatment with pegIFN alfa-2b + RIB (in comparison with pegIFN alfa-2a + RIB) is an efficient strategy although it depends on acquisition prices, and so, it would be rarely useful in other centres. In our hospital it would produce a budgetary saving that would range from 71,358 to 80,986 euros, which would represent a 7,5-8,6% of the total cost of the pharmacological treatment of the CHC
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
M.A. Casado Gómez, L. Álvarez-Rubio, S. Miró Manero, E.L. Mariño Hernández, M. Buti Ferret,